BRPI0507998A - uso de um inibidor de serina palmitoiltransferase (spt) para tratar aterosclerose e dislipidemia - Google Patents

uso de um inibidor de serina palmitoiltransferase (spt) para tratar aterosclerose e dislipidemia

Info

Publication number
BRPI0507998A
BRPI0507998A BRPI0507998-5A BRPI0507998A BRPI0507998A BR PI0507998 A BRPI0507998 A BR PI0507998A BR PI0507998 A BRPI0507998 A BR PI0507998A BR PI0507998 A BRPI0507998 A BR PI0507998A
Authority
BR
Brazil
Prior art keywords
spt
inhibitor
dyslipidemia
serine palmitoyltransferase
treat atherosclerosis
Prior art date
Application number
BRPI0507998-5A
Other languages
English (en)
Inventor
Reynold Homan
Sotirios Konstant Karathanasis
Robert Lee Panek
Tae-Sik Park
Mark David Rekhter
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of BRPI0507998A publication Critical patent/BRPI0507998A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/345—Nitrofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

USO DE UM INIBIDOR DE SERINA PALMITOILTRANSFERASE (SPT) PARA TRATAR ATEROSCLEROSE E DISLIPIDEMIA . A presente invenção refere-se a métodos para tratar aterosclerose, dislipidemia, outras doenças cardiovasculares e doenças relacionadas, tal como diabete, empregando um inibidor de serina palmitoiltransferase (SPT). A presente invenção também se refere a composições farmacêuticas e kits que compreendem um inibidor de serina palmitoiltransferase (SPT), opcionalmente com outro agente farmacêutico.
BRPI0507998-5A 2004-03-26 2005-03-21 uso de um inibidor de serina palmitoiltransferase (spt) para tratar aterosclerose e dislipidemia BRPI0507998A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55702104P 2004-03-26 2004-03-26
PCT/IB2005/000733 WO2005092325A1 (en) 2004-03-26 2005-03-21 Use of a serine palmitoyltransferase (spt) inhibitor to treat atherosclerosis and dyslipidemia

Publications (1)

Publication Number Publication Date
BRPI0507998A true BRPI0507998A (pt) 2007-07-31

Family

ID=34961685

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507998-5A BRPI0507998A (pt) 2004-03-26 2005-03-21 uso de um inibidor de serina palmitoiltransferase (spt) para tratar aterosclerose e dislipidemia

Country Status (6)

Country Link
US (1) US20080027088A1 (pt)
EP (1) EP1732538A1 (pt)
JP (1) JP2007530528A (pt)
BR (1) BRPI0507998A (pt)
CA (1) CA2560920A1 (pt)
WO (1) WO2005092325A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1795206A4 (en) * 2004-08-11 2009-07-22 Chugai Pharmaceutical Co Ltd MEDICAMENT FOR THE TREATMENT OF HCV OR THE PREVENTION OF HCV INFECTION
EP1923060A1 (en) * 2006-11-08 2008-05-21 Nederlandse Organisatie voor Toegepast-Natuuurwetenschappelijk Onderzoek TNO Combinations of a sphingolipid and an HMG-CoA reductase inhibitor for treating hypercholesterolemia
US20090264528A1 (en) * 2008-04-18 2009-10-22 The Research Foundation Of State University Of New York Serine palmitoylcoa transferase (spt) inhibition by myriocin or genetic deficiency decreases cholesterol absorption
US20090264514A1 (en) * 2008-04-18 2009-10-22 The Research Foundation Of State University Of New York SPHINGOMYELIN SYNTHASE 2 (SMS2) DEFICIENCY ATTENUATES NFkB ACTIVATION, A POTENTIAL ANTI-ATHEROGENIC PROPERTY
TW201010692A (en) * 2008-06-19 2010-03-16 Public Univ Corp Nagoya City Univ Pharmaceutical composition for treatment or prevention of hbv infection
EP2368989A4 (en) 2008-11-26 2012-09-26 Chugai Pharmaceutical Co Ltd OLOGORIBONUCLEOTIDE OR PEPTIDE NUCLEIC ACID CAPABLE OF INHIBITING HEPATITIS C VIRUS ACTIVITY
ITMI20090284A1 (it) 2009-02-26 2010-08-27 Consiglio Nazionale Ricerche Uso di inibitori della serina palmitoiltrasferasi per la prevenzione e il rallentamento delle degenerazioni retiniche ereditarie e relative composizioni
EP2526426A1 (en) * 2010-01-20 2012-11-28 Universität Zürich Method for assaying diseases characterised by dyslipidemia
WO2011104298A1 (en) * 2010-02-24 2011-09-01 Universität Zürich Prevention and treatment of diseases caused by elevated levels of deoxy-sphingolipids
EP3293522A3 (en) 2010-06-20 2018-05-02 Zora Biosciences OY Lipidomic biomarkers for identification of high-risk coronary artery disease patients
KR101384349B1 (ko) 2010-12-30 2014-04-24 충북대학교 산학협력단 세린-팔미토일트랜스퍼라아제 활성 저해제를 유효성분으로 포함하는 항암용 조성물
WO2013078395A1 (en) 2011-11-21 2013-05-30 The Institute For Ethnomedicine L-serine compositions, methods and uses for treating neurodegenerative diseases and disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6190894B1 (en) * 1993-03-19 2001-02-20 The Regents Of The University Of California Method and compositions for disrupting the epithelial barrier function
US5989803A (en) * 1997-09-05 1999-11-23 The Trustees Of Columbia University In The City Of New York Method for treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase
WO2002048325A2 (en) * 2000-12-15 2002-06-20 Bayer Aktiengesellschaft Regulation of human serine palmitoyltransferase

Also Published As

Publication number Publication date
CA2560920A1 (en) 2005-10-06
JP2007530528A (ja) 2007-11-01
WO2005092325A1 (en) 2005-10-06
US20080027088A1 (en) 2008-01-31
EP1732538A1 (en) 2006-12-20

Similar Documents

Publication Publication Date Title
BRPI0507998A (pt) uso de um inibidor de serina palmitoiltransferase (spt) para tratar aterosclerose e dislipidemia
AR070497A1 (es) Composicion detergente que comprende lipasa
CL2010001483A1 (es) Compuestos derivados de 5-fenil-1h-piridin-2-ona y 6-fenil-2h-piridazin-3-ona, inhibidores de tirosina-quinasa (btk); composicion farmaceutica que comprende a dichos compuestos y su uso para el tratamiento de un estado patologico inflamatorio y/o autoinmune.
CL2011000527A1 (es) Compuestos derivados de benzofurano; composicion farmaceutica que los comprende;y su uso en el tratamiento de la hepatitis c.
CL2007002867A1 (es) Compuestos derivados de 2-(bencimidazolil)purina, inhibidores de janus quinasa 3; composicion farmaceutica que los contiene; y su uso para tratar enfermedades autoinmune, inflamatorias, cardiovasculares, rechazo de implante, entre otras.
CL2008000873A1 (es) Compuestos derivados de pirrolidin amidas; composicion farmaceutica que comprende dichos compuestos; y su uso para tratar trombosis.
CL2008002319A1 (es) Compuestos derivados de pirrolopirimidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
CL2007001674A1 (es) Compuestos derivados de heterociclos, inhibidores de aspartil proteasa; composicion farmaceutica que los comprende;y su uso para tratar enfermedades cardiovasculares,cognitivas y neurodegenerativas.
UY29246A1 (es) Nuevos compuestos
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
CR20140313A (es) Compuestos de biaril éter urea
NI200900093A (es) Compuestos que modulan la actividad de c-fms y/o c-kit y uso de los mismos.
CU20070160A7 (es) Pirrolopirazoles, inhibidores potentes de quinasa
UY31806A (es) Compuestos de tiazole y oxazole de sulfonamida de benceno
ECSP10010735A (es) Compuestos químicos 251
CL2007001391A1 (es) Compuestos derivados de pirrolidinas sustituidas, inhibidores del factor xa y/o inhibidores sobre la serina proteasa; composicion farmaceutica que comprende a dichos compuestos; proedimiento para preparar la composicon farmaceutica; y uso de los compuestos preparar un medicamneto con un efecto antitrombotico
ECSP078013A (es) Inhibidores heterocíclicos de mek y métodos de uso de ellos
BRPI0512624A (pt) compostos heteroarila e fenilsulfamoìla substituìdos
NO20081636L (no) FAP - inhibitorer
ECSP099529A (es) Inhibidores de cinasa mapk/erk
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
UY30304A1 (es) Moduladores de mglur5 i
BRPI0510665A (pt) 3-(4-heteroarilcicloexilamino) ciclopentano-carboxiamidas como moduladores de receptores de quimiocinas
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
CL2007002971A1 (es) Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A E 6A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE A 8.6 NA RPI 2099 DE 29/03/2011.